SeNostic GmbH, a Braunschweig, Germany-based diagnostics company, raised a seed round of funding of undisclosed amount.
The round was led by High-Tech Gründerfonds (HTGF).
The company intends to use the funds for the clinical development of a novel technology for the differential diagnosis of neurodegenerative diseases.
Founded in 2014 by Dr. Thorsten Lührs, managing director, and Dr. Christiane Ritter, CSO, SeNostic focuses on the development and marketing of novel technologies for the diagnosis of neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease and dementia with Lewy-bodies. Currently, the company is validating its SeedCycler analytical platform for the amplification, characterization and quantification of diverse seed biomarkers based on their biophysical properties, which is not yet commercially available.